FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPR

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average b	urden									
hours per response:	0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

200 CONNELL DRIVE, SUITE 1500 4. If Amendment, Date of Original Filed (Street) BERKELEY HEIGHTS NJ (City) (State) (Zip) Check this box to indicate that a transational state of the	Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
200 CONNELL DRIVE, SUITE 1500 4. If Amendment, Date of Original Filed (Street) BERKELEY HEIGHTS NJ	Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
200 CONNELL DRIVE, SUITE 1500 4. If Amendment, Date of Original Filed (Street) BERKELEY NL 07922	Line) X Form filed by One Reporting Person Form filed by More than One Reporting
C/O CTCEACEE FILARMACEO FICAES, INC.,	
C/O CYCLACEL PHARMACEUTICALS, INC.,	See Remarks
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/I 06/30/2023	n/Day/Year) X Officer (give title Other (specify below) below)
1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading S <u>McBarron Paul</u> 2. Usuer Name and Ticker or Trading S	

Code V Amount (A) or (D) Price Reported Transaction(s) (Instr. 3 and 4) (Instr. 4)	1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)				Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
								Price	Transaction(s)		(instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (right to buy)	\$0.5891	06/30/2023		A		70,200		06/30/2024	06/30/2033	Common Stock	70,200	\$0 ⁽¹⁾	70,200	D	

Explanation of Responses:

1. The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement.

Remarks:

E. VP, Fin, CFO, COO and Secretary

/s/ Paul McBarron

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

07/03/2023 Date